Research Topics
| Nelson B WattsSummaryAffiliation: University of Cincinnati Country: USA Publications
| Collaborators
|
Detail Information
Publications
Risedronate on 2 consecutive days a month reduced vertebral fracture risk at 1year compared with historical placeboNelson B Watts
Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA
J Clin Densitom 13:56-62. 2010..The use of appropriate historical control data may provide an alternative design to assess fracture effects in osteoporosis trials for which simultaneous placebo-controlled data are unavailable...
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture riskNelson B Watts
University of Cincinnati Osteoporosis Center, Cincinnati, OH, USA
J Clin Densitom 7:255-61. 2004..Although patients showing an increase in BMD had a lower fracture risk than patients showing a decrease in BMD, greater increases in BMD did not necessarily predict greater decreases in fracture risk...- Bisphosphonates in the treatment of osteoporosisDima L Diab
Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Cincinnati VA Medical Center, University of Cincinnati, 3125 Eden Avenue, PO Box 670547, Cincinnati, OH 45267, USA
Endocrinol Metab Clin North Am 41:487-506. 2012..For most patients with osteoporosis, the benefits of treatment outweigh the risks... - Is it ethical to use placebos in osteoporosis clinical trials?Nelson B Watts
Bone Health and Osteoporosis Center, University of Cincinnati College of Medicine, 222 Piedmont Avenue, Suite 4300, Cincinnati, OH 45219, USA
Curr Osteoporos Rep 2:31-6. 2004.... - Fundamentals and pitfalls of bone densitometry using dual-energy X-ray absorptiometry (DXA)Nelson B Watts
University of Cincinnati Bone Health and Osteoporosis Center, 222 Piedmont Avenue, Suite 4300, Cincinnati, OH 45219, USA
Osteoporos Int 15:847-54. 2004..This paper reviews the fundamentals of positioning, scan analysis, and interpretation for central DXA and highlights some of the common pitfalls that may lead to erroneous results... 
Dynamic bone quality: a noninvasive measure of bone's biomechanical property in osteoporosisAmit Bhattacharya
Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH, USA
J Clin Densitom 13:228-36. 2010....- Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatmentNelson B Watts
University of Cincinnati, Cincinnati, Ohio 45219 4231, USA
J Bone Miner Res 24:1125-31. 2009..In conclusion, loss of FN BMD at 12 mo in postmenopausal women with osteoporosis treated with TPTD is nevertheless consistent with a good treatment response in terms of VF risk reduction... - Risedronate prevents new vertebral fractures in postmenopausal women at high riskNelson B Watts
University of Cincinnati, Cincinnati, Ohio 45219, USA
J Clin Endocrinol Metab 88:542-9. 2003..Significant reduction in fracture risk after 1 yr is an important benefit in patients at high risk for fracture because, without treatment, these patients are likely to sustain new fractures in the near term... - Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronateNelson B Watts
University of Cincinnati, Cincinnati, Ohio 45219, USA
Osteoporos Int 14:437-41. 2003..The use of appropriate historical control data provides an approach to the assessment of fracture effects in osteoporosis trials for which placebo-controlled data are not available... - Risk factors for the development of osteoporosis and osteoporotic fractures among older menMaria Thomas-John
Division of Immunology, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH 45267 0563, USA
J Rheumatol 36:1947-52. 2009.... - Long-term use of bisphosphonates in osteoporosisNelson B Watts
University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati, Ohio 45219, USA
J Clin Endocrinol Metab 95:1555-65. 2010..Uncommon side effects have emerged in postapproval use. Because bisphosphonates accumulate in bone and are released for months or years after treatment is stopped, it is reasonable to consider the clinical question of how long to treat... - Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims databaseNelson B Watts
University of Cincinnati Bone Health and Osteoporosis Center, 222 Piedmont Ave, Suite 4300, Cincinnati, OH, 45219, USA
J Manag Care Pharm 10:142-51. 2004.... - The Fracture Risk Assessment Tool (FRAX®): applications in clinical practiceNelson B Watts
University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati, OH 45219, USA
J Womens Health (Larchmt) 20:525-31. 2011..Acceptance and clinical use of FRAX may help identify men and women at increased risk for osteoporotic fracture, but implementing the tool into clinical practice may be a challenge for busy physicians... - Is it ethical to use placebos in osteoporosis clinical trials?Nelson B Watts
Bone Health and Osteoporosis Center, University of Cincinnati College of Medicine, 222 Piedmont Avenue, Suite 4300, Cincinnati, OH 45219, USA
Curr Rheumatol Rep 6:79-84. 2004.... - Bisphosphonate treatment of osteoporosisNelson B Watts
University of Cincinnati College of Medicine, University of Cincinnati Bone Health and Osteoporosis Center, Cincinnati, OH, USA
Clin Geriatr Med 19:395-414. 2003.... - Diagnosis and evaluation of patients with osteoporosisNelson B Watts
University of Cincinnati College of Medicine, Bone Health and Osteoporosis Center, 222 Piedmont Avenue, Suite 4300, Cincinnati, OH 45219, USA
South Med J 97:540-1. 2004 - A label-free electronic biosensor for detection of bone turnover markersYeo Heung Yun
Nanoworld and Smart Materials and Devices Laboratory, College of Engineering, University of Cincinnati, Cincinnati, OH 45221, USA E mail
Sensors (Basel) 9:7957-69. 2009..It is hoped that analysis of bone turnover markers can indicate the beginning of bone diseases such as osteoarthritis and osteoporosis so that treatment might start early when it is most effective... - Intraoperative PTH: effect of sample timing and vitamin D statusMelissa McCarty Statham
Department of Otolaryngology Head and Neck Surgery, University of Cincinnati School of Medicine, Cincinnati, OH, USA
Otolaryngol Head Neck Surg 136:946-51. 2007..To assess the effect of timing of intraoperative parathormone (iPTH) samples and 25-hydroxyvitamin D (25-OHD) status on decision-making during parathyroidectomy... - Hyperbilirubinemia is not a major contributing factor to altered bone mineral density in patients with chronic liver diseaseDarcey L H Smith
Division of Digestive Diseases, University of Cincinnati, Cincinnati, OH 45267-0595, USA
J Clin Densitom 9:105-13. 2006.... - Therapies to improve bone mineral density and reduce the risk of fracture: clinical trial resultsNelson B Watts
Department of Medicine, University of Cincinnati College of Medicine, OH, USA
J Reprod Med 47:82-92. 2002..Other strategies include nonpharmacologic interventions, such as calcium supplements, vitamin D and exercise... - Osteonecrosis of the jawNelson B Watts
Department of Internal Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Cincinnati College of Medicine, Cincinnati, OH, USA
South Med J 101:160-5. 2008..v. bisphosphonate therapy for cancer. Patients with osteoporosis receiving lower-dose bisphosphonate therapy do not require special precautions, but should be informed of the low risk of this complication... - Comparison of serum calcium change following thyroid and nonthyroid neck surgeryNicholas Mehta
Dept of Otolaryngology-Head and Neck Surgery, Cincinnati, Ohio 45267-0001, USA
Otolaryngol Head Neck Surg 134:901-6. 2006..Postoperative calcium monitoring should be similar following total and completion thyroidectomy due to similar rates of hypocalcemia and mean calcium drops. EBM rating: B-3b...